Back to search results

Understanding Right Heart Function in Heart Failure

This observational study is looking at how the right side of the heart works in people who have heart failure with reduced ejection fraction (HFrEF), which means the heart's main pumping chamber doesn't squeeze as well as it should. It also focuses on those with pulmonary hypertension (high blood pressure in the lungs). Researchers want to find better ways to identify and treat problems with the right side of the heart, which can make heart failure worse. They will study adults aged 18 to 90 who have HFrEF and can safely stop certain blood thinners (like direct oral anticoagulants or vitamin K antagonists) for 48 hours before a procedure. The main goal is to see how accurate different ways of checking heart function are over five years.

Study design
This is an observational study planning to enroll 50 participants. It will look at how the right side of the heart works in people with heart failure.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for five years to assess the accuracy of diagnostic methods.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06299436

Hemodynamic Assessment of underLying myocyTe Function in Right Heart Failure

Recruiting
Not specifiedAges 18–90Observational
Johns Hopkins University
~50 participants
Updated 2026-01-12 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Diagnostic accuracy based on Area Under Curve (AUC)
Measured over 5 years

Conditions

Heart Failure With Reduced Ejection Fraction
Pulmonary Hypertension
Right Heart Failure Due to Left Heart Failure

Explore related trials

Heart failure with reduced ejection fractionPulmonary HypertensionRight Heart Failure

Where it's being run

1 sites across 1 states
Maryland1

Study leadership

  • Steven Hsu, MD · PRINCIPAL_INVESTIGATOR · Johns Hopkins School of Medicine

Who to contact

Steven Hsu, MD
[email protected]
410-502-0955
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients aged between 18 and 90 years of age
Diagnosed with heart failure with reduced ejection fraction (LV ejection fraction ≤ 40-50%)
Can safely hold direct oral anticoagulant (DOAC) vitamin K antagonist (VKA) for 48 hours prior to the procedure

Exclusion

Unable to interrupt VKA anticoagulation
Point of care International Normalized Ratio (INR) \> 1.5
Pregnant patients
Acute hospitalization or decompensation within 2 weeks prior to study date
Participation in a study involving an investigational drug within 4 weeks prior to study date
Inability to lie flat in the supine position
Symptomatic hemodynamic instability at rest or during the procedure

What this trial measures

  • Diagnostic accuracy based on Area Under Curve (AUC)5 years

    Diagnostic accuracy (AUC), as determined by combination of sensitivity and specificity, of multiple clinical metrics will be compared to determine which best identifies underlying right ventricular myocyte contractile dysfunction.